L-Glutamine için Irritable Bowel Syndrome (IBS)
C Kanıt Küçük çalışmalardan sınırlı kanıt mevcuttur, ancak bazı olumlu sinyaller bulunmaktadır.Pilot RCTs suggest glutamine (5 g TID) reduces intestinal permeability and IBS-D symptoms in post-infectious IBS. Promising but needs larger trials.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dl\u002Dglutamine\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
Sonuç
Pilot RCTs suggest glutamine (5 g TID) reduces intestinal permeability and IBS-D symptoms in post-infectious IBS. Promising but needs larger trials.
Key Study Findings
Other
Unraveling the active ingredients and molecular mechanisms of Qinghua Changyan granule against irritable bowel syndrome …
Dose: None
vs: None
Outcome: IBS-D symptom relief via gut microbiota and glutamine …
Etki: None
None
Popülasyon: animal model of IBS with diarrhea
Other
n=25
4 weeks
Effect of probiotic administration of Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917 …
Dose: Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917
vs: phosphate-buffered saline (PBS)
Outcome: visceral hypersensitivity (abdominal withdrawal reflex scores)
Etki: None
p<0.05
Popülasyon: female rats with water avoidance stress-induced IBS-D model
Other
n=62
[Study on activation mechanism of SGCs in representation along the distribution of stomach meridian in …
Dose: None
vs: Control group (no citrobacter)
Outcome: SGC activation in DRG segments
Etki: None
P<0.05 to P<0.01
Popülasyon: Male C57BL/6 mice (IBS-D model)
Review
Intestinal Barrier Impairment, Preservation, and Repair: An Update.
Dose: None
vs: None
Outcome: Intestinal barrier preservation and repair
Etki: None
None
Popülasyon: IBD and IBS patients (review)
Other
Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes.
Dose: None
vs: None
Outcome: Cholesterol levels
Etki: None
None
Popülasyon: Mouse model
In Vitro
Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability …
Dose: None
vs: None
Outcome: inflammation markers
Etki: None
None
Popülasyon: Mice
Key Statistics
2
Çalışmalar
150
Katılımcılar
↑
Positive
C
Derece
Referenced Papers
Fitoterapia
2026
1 atıf
Journal of the …
2026
Zhongguo zhen jiu …
2025
Nutrients
2024
47 atıf
Cannabis and cannabinoid …
2024
10 atıf
International journal of …
2023
9 atıf
Journal of gastroenterology
2022
23 atıf
NeuroImage. Clinical
2022
8 atıf
Digestion
2021
29 atıf
Frontiers in nutrition
2021
17 atıf
Medicine
2021
Nutrition research (New …
2020
42 atıf
World journal of …
2020
11 atıf
Gut
2019
148 atıf
Metabolomics : Official …
2019
41 atıf
Pain
2019
23 atıf
Scientific reports
2019
14 atıf
Gut
2019
5 atıf
[Not Available].
RCT
Praxis
2018
Current opinion in …
2017
71 atıf
JPEN. Journal of …
2016
44 atıf
Gastroenterology
2015
17 atıf
Frontline gastroenterology
2012
20 atıf
The American journal …
2011
48 atıf
Clinical nutrition (Edinburgh, …
2011
12 atıf
MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome.
Other
Gut
2010
263 atıf
Clinics (Sao Paulo, …
2010
47 atıf
Zhong xi yi …
2009
6 atıf
Journal of clinical …
2008
73 atıf
Nutrition in clinical …
2008
42 atıf
Journal of proteome …
2006
80 atıf
Medycyna wieku rozwojowego
2004
1 atıf
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Yaygın Kullanılan Dozajlar
- general:
- 5-15 g/day
- ibsdsupport:
- 5 g three times daily (15 g/day total)
- postexercisegut:
- 0.25-0.9 g/kg before intense exercise
- gutbarriersupport:
- 0.5 g/kg/day (approximately 30-40 g/day for adults)
Üst sınır: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day
Araştırmalarda İncelenen Dozajlar
| Dozaj | Süre | Etki | N |
|---|---|---|---|
| None | -- | Positive | -- |
| Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917 | 4 weeks | Positive | 25 |
| None | -- | Mixed | 62 |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Negative | 75 |
En iyi alım zamanı: Between meals or before exercise; divide doses throughout the day
Safety & Side Effects
Bildirilen Yan Etkiler
- ⚠ Mild gastrointestinal discomfort at high doses
- ⚠ Headache
- ⚠ Dizziness at very high doses
- ⚠ Potential glutamate excitotoxicity concerns in neurological conditions (theoretical)
Bilinen Etkileşimler
- ● Lactulose (glutamine may reduce the efficacy of lactulose for hepatic encephalopathy)
- ● Anti-seizure medications (glutamine converts to glutamate; theoretical concern)
- ● Chemotherapy agents (glutamine may protect cancer cells; discuss with oncologist)
Tolere edilebilir üst alım: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day
Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.
Frequently Asked Questions
Does L-Glutamine help with Irritable Bowel Syndrome (IBS)?
Based on 2 studies with 150 participants, there is limited but promising evidence that L-Glutamine may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is C (Some Evidence).
How much L-Glutamine should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 5-15 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of L-Glutamine?
Reported side effects may include Mild gastrointestinal discomfort at high doses, Headache, Dizziness at very high doses, Potential glutamate excitotoxicity concerns in neurological conditions (theoretical). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for L-Glutamine and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.
Related Evidence
Şu durum için diğer içerikler: Irritable Bowel Syndrome (IBS)
L-Glutamine diğer sağlık durumları için
References
- [1] Jiayu Yang et al.. Fitoterapia. 2026. Unraveling the active ingredients and molecular mechanisms of Qinghua Changyan granule against irritable bowel syndrome with diarrhea: Effects on gut … doi:10.1016/j.fitote.2025.106960 PubMed
- [2] Nazila Dardmeh et al.. J Sci Food Agric. 2026. Effect of probiotic administration of Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917 on metabolic profiles in an … doi:10.1002/jsfa.70190 PubMed
- [3] Na Li et al.. Zhongguo Zhen Jiu. 2025. [Study on activation mechanism of SGCs in representation along the distribution of stomach meridian in IBS-D mice]. doi:10.13703/j.0255-2930.20241126-0001 PubMed
- [4] Ayah Matar et al.. Nutrients. 2024. Intestinal Barrier Impairment, Preservation, and Repair: An Update. doi:10.3390/nu16203494 PubMed
- [5] Mengxue He et al.. Cannabis Cannabinoid Res. 2024. Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes. doi:10.1089/can.2022.0331 PubMed
- [6] Ludovic D Langlois et al.. Int J Mol Sci. 2023. Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability in a Chronic-Restraint Stress Model. doi:10.3390/ijms24087220 PubMed
- [7] Yukari Tanaka et al.. J Gastroenterol. 2022. Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation. doi:10.1007/s00535-022-01888-2 PubMed
- [8] Nawroz Barazanji et al.. Neuroimage Clin. 2022. Irritable bowel syndrome in women: Association between decreased insular subregion volumes and gastrointestinal symptoms. doi:10.1016/j.nicl.2022.103128 PubMed
- [9] Min Li et al.. Digestion. 2021. Glutamine Blocks Interleukin-13-Induced Intestinal Epithelial Barrier Dysfunction. doi:10.1159/000502953 PubMed
- [10] Samira Rastgoo et al.. Front Nutr. 2021. Glutamine Supplementation Enhances the Effects of a Low FODMAP Diet in Irritable Bowel Syndrome Management. doi:10.3389/fnut.2021.746703 PubMed
- [11] Yong Zhang et al.. Medicine (Baltimore). 2021. To assess the effective and safety of compound glutamine entersoluble capsules in irritable bowel syndrome: A protocol for systematic review … doi:10.1097/MD.0000000000025098 PubMed
- [12] Karin Ried et al.. Nutr Res. 2020. Herbal formula improves upper and lower gastrointestinal symptoms and gut health in Australian adults with digestive disorders. doi:10.1016/j.nutres.2020.02.008 PubMed
- [13] Magdy El-Salhy. World J Gastroenterol. 2020. Possible role of intestinal stem cells in the pathophysiology of irritable bowel syndrome. doi:10.3748/wjg.v26.i13.1427 PubMed
- [14] QiQi Zhou et al.. Gut. 2019. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. doi:10.1136/gutjnl-2017-315136 PubMed
- [15] Mai Yamamoto et al.. Metabolomics. 2019. Metabolomics reveals elevated urinary excretion of collagen degradation and epithelial cell turnover products in irritable bowel syndrome patients. doi:10.1007/s11306-019-1543-0 PubMed
- [16] Olga Bednarska et al.. Pain. 2019. Reduced excitatory neurotransmitter levels in anterior insulae are associated with abdominal pain in irritable bowel syndrome. doi:10.1097/j.pain.0000000000001589 PubMed
- [17] Adriane Icenhour et al.. Sci Rep. 2019. Elucidating the putative link between prefrontal neurotransmission, functional connectivity, and affective symptoms in irritable bowel syndrome. doi:10.1038/s41598-019-50024-3 PubMed
- [18] Alexander Charles Ford et al.. Gut. 2019. Efficacy of glutamine in postinfection IBS. doi:10.1136/gutjnl-2018-317438 PubMed
- [19] Johann Steurer. Praxis (Bern 1994). 2018. [Not Available]. doi:10.1024/1661-8157/a003109 PubMed
- [20] Najate Achamrah et al.. Curr Opin Clin Nutr Metab Care. 2017. Glutamine and the regulation of intestinal permeability: from bench to bedside. doi:10.1097/MCO.0000000000000339 PubMed
- [21] Julien Bertrand et al.. JPEN J Parenter Enteral Nutr. 2016. Glutamine Restores Tight Junction Protein Claudin-1 Expression in Colonic Mucosa of Patients With Diarrhea-Predominant Irritable Bowel Syndrome. doi:10.1177/0148607115587330 PubMed
- [22] Moïse Coëffier et al.. Gastroenterology. 2015. Intestinal permeability in patients with diarrhea-predominant irritable bowel syndrome: is there a place for glutamine supplementation? doi:10.1053/j.gastro.2015.02.057 PubMed
- [23] Melissa A Smith et al.. Frontline Gastroenterol. 2012. Nutritional management of adults with inflammatory bowel disease: practical lessons from the available evidence. doi:10.1136/flgastro-2011-100032 PubMed
- [24] David M Niddam et al.. Am J Gastroenterol. 2011. Reduced hippocampal glutamate-glutamine levels in irritable bowel syndrome: preliminary findings using magnetic resonance spectroscopy. doi:10.1038/ajg.2011.120 PubMed
- [25] Khaly Mbodji et al.. Clin Nutr. 2011. Alanyl-glutamine restores maternal deprivation-induced TLR4 levels in a rat neonatal model. doi:10.1016/j.clnu.2011.04.002 PubMed
- [26] QiQi Zhou et al.. Gut. 2010. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. doi:10.1136/gut.2009.181834 PubMed
- [27] Jean Robert Rapin et al.. Clinics (Sao Paulo). 2010. Possible links between intestinal permeability and food processing: A potential therapeutic niche for glutamine. doi:10.1590/S1807-59322010000600012 PubMed
- [28] Wen-yan Gao et al.. Zhong Xi Yi Jie He Xue Bao. 2009. [Effects of Changjishu soft elastic capsule in treatment of diarrhea-predominant irritable bowel patients with liver-qi stagnation and spleen deficiency syndrome: … doi:10.3736/jcim20090303 PubMed
- [29] Angelo Andriulli et al.. J Clin Gastroenterol. 2008. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized … doi:10.1097/MCG.0b013e31817fadd6 PubMed
- [30] Arnold Wald et al.. Nutr Clin Pract. 2008. Behavioral and complementary approaches for the treatment of irritable bowel syndrome. doi:10.1177/0884533608318677 PubMed
- [31] Francois-Pierre J Martin et al.. J Proteome Res. 2006. Transgenomic metabolic interactions in a mouse disease model: interactions of Trichinella spiralis infection with dietary Lactobacillus paracasei supplementation. doi:10.1021/pr060157b PubMed
- [32] Barbara Kamińska et al.. Med Wieku Rozwoj. 2004. [Environmental factors in the etiopathology of inflammatory bowel syndrome]. PubMed
FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.